Overview
Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C
Status:
Completed
Completed
Trial end date:
2006-04-01
2006-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Vertex Pharmaceuticals IncorporatedTreatments:
Interferon-alpha
Peginterferon alfa-2a
Ribavirin
Criteria
Inclusion Criteria:- Infected with hepatitis C virus
Exclusion Criteria:
- Contraindications to peginterferon or ribavirin therapy.